Hetero, Cipla's Remdesivirs Hit India Market, 'Surplus' Envisaged By August
Prices Well Below $100/vial
Executive Summary
Gilead licensees Hetero and Cipla introduce remdesivir, the antiviral seen as a potential treatment for COVID-19, in India. Pricing plans will be closely watched and supplies in the country are expected to stabilize soon, possibly turning to a surplus situation in several months.
You may also be interested in...
Cipla’s Proventil Rival Gnaws At US Market
Cipla’s generic of Merck & Co’s Proventil makes significant inroads in the US, with the Indian company confident that it has both a strong cost position and large capacity to take on competition. Pricing in the segment currently remains ‘respectable.’
Cipla’s Proventil Generic Gnaws At US Market
Cipla’s generic of Merck & Co’s Proventil makes significant inroads in the US, with the Indian company confident that it has both a strong cost position and large capacity to take on competition. Pricing in the segment currently remains ‘respectable’.
Coronavirus Update: Gilead To Meet Global Remdesivir Demand By October
Ramp-up is possible thanks to increased internal capacity and network of voluntary licensing partners including Mylan, Cipla and Dr Reddy's.
Need a specific report? 1000+ reports available
Buy Reports